I’m an oncologist who treats prostate cancer. For many patients and their manhood, the cure seems worse than the disease.
First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis
Integrating machine-generated mortality estimates and behavioral nudges to promote serious illness conversations for cancer patients: Design and methods for a stepped-wedge cluster randomized controlled trial
Association of Utilization Management Policy With Uptake of Hypofractionated Radiotherapy Among Patients With Early-Stage Breast Cancer
Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment
Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018
Effect of Integrating Machine Learning Mortality Estimates With Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients With Cancer: A Stepped-Wedge Cluster Randomized Clinical Trial
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice
Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer
Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer
Characteristics of Physicians Participating in Medicare’s Oncology Care Model Bundled Payment Program
New Mexico Cancer Center and the COME HOME Model: Pathways improving the value of community-based cancer care
Development and Application of a Machine Learning Approach to Assess Short-term Mortality Risk Among Patients With Cancer Starting Chemotherapy
High content screen for identifying small-molecule LC3B-localization modulators in a renal cancer cell line
Scalable principles of community-based high-value care for seriously ill individuals: Diamonds in the rough
